FMP
Nanobiotix S.A.
NBTX
NASDAQ
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
3.34 USD
0.031 (0.928%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
56.51k
11.3k
5.4M
40.92M
-13.12M
-13.78M
-14.46M
-15.19M
-15.95M
-16.74M
Revenue %
-
-80
47.66k
658.12
-132.06
5
5
5
5
Ebitda
-35.59M
-51.54M
-51.03M
-26.77M
-65.91M
7.31M
7.68M
8.06M
8.47M
8.89M
Ebitda %
-62.99k
-456.05k
-945.37
-65.42
502.4
-53.08
-53.08
-53.08
-53.08
Ebit
-37.58M
-53.3M
-52.72M
-27.39M
-67.75M
7.35M
7.72M
8.11M
8.51M
8.94M
Ebit %
-66.5k
-471.65k
-976.78
-66.94
516.37
-53.39
-53.39
-53.39
-53.39
Depreciation
1.98M
1.76M
1.7M
622.71k
1.83M
-6.03M
-6.33M
-6.65M
-6.98M
-7.33M
Depreciation %
3.51k
15.6k
31.41
1.52
-13.96
43.79
43.79
43.79
43.79
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
134.66M
94.84M
46.77M
85.08M
56.21M
-8.27M
-8.68M
-9.11M
-9.57M
-10.05M
Total Cash %
238.3k
839.21k
866.58
207.92
-428.43
60
60
60
60
Receivables
4.38M
7.83M
114.14k
3.35M
9.65M
-3.77M
-3.96M
-4.16M
-4.36M
-4.58M
Receivables %
7.76k
69.26k
2.11
8.19
-73.52
27.36
27.36
27.36
27.36
Inventories
-45.57M
-3.44M
3.37M
226.03k
-
3.78M
3.96M
4.16M
4.37M
4.59M
Inventories %
-80.64k
-30.43k
62.42
0.55
-
-27.41
-27.41
-27.41
-27.41
Payable
6.3M
5.65M
4.52M
7.57M
5.07M
-7.26M
-7.63M
-8.01M
-8.41M
-8.83M
Payable %
11.15k
49.96k
83.73
18.49
-38.63
52.72
52.72
52.72
52.72
Cap Ex
-120.93k
-263.32k
-105.1k
-380.86k
-958.37k
5.59M
5.87M
6.16M
6.47M
6.79M
Cap Ex %
-214
-2.33k
-1.95
-0.93
7.3
-40.58
-40.58
-40.58
-40.58
Weighted Average Cost Of Capital
Price
3.34
Beta
Diluted Shares Outstanding
47.27M
Costof Debt
15.89
Tax Rate
After Tax Cost Of Debt
15.89
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
57.53M
Total Equity
157.91M
Total Capital
215.44M
Debt Weighting
26.7
Equity Weighting
73.3
Wacc
12.48
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
56.51k
11.3k
5.4M
40.92M
-13.12M
-13.78M
-14.46M
-15.19M
-15.95M
-16.74M
Ebitda
-35.59M
-51.54M
-51.03M
-26.77M
-65.91M
7.31M
7.68M
8.06M
8.47M
8.89M
Ebit
-37.58M
-53.3M
-52.72M
-27.39M
-67.75M
7.35M
7.72M
8.11M
8.51M
8.94M
Tax Rate
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
Ebiat
-37.59M
-53.31M
-52.73M
-27.47M
-67.85M
7.35M
7.72M
8.11M
8.51M
8.94M
Depreciation
1.98M
1.76M
1.7M
622.71k
1.83M
-6.03M
-6.33M
-6.65M
-6.98M
-7.33M
Receivables
4.38M
7.83M
114.14k
3.35M
9.65M
-3.77M
-3.96M
-4.16M
-4.36M
-4.58M
Inventories
-45.57M
-3.44M
3.37M
226.03k
-
3.78M
3.96M
4.16M
4.37M
4.59M
Payable
6.3M
5.65M
4.52M
7.57M
5.07M
-7.26M
-7.63M
-8.01M
-8.41M
-8.83M
Cap Ex
-120.93k
-263.32k
-105.1k
-380.86k
-958.37k
5.59M
5.87M
6.16M
6.47M
6.79M
Ufcf
11.76M
-98.03M
-51.36M
-24.28M
-75.54M
4.22M
6.89M
7.24M
7.6M
7.98M
Wacc
12.48
12.48
12.48
12.48
12.48
Pv Ufcf
3.75M
5.45M
5.09M
4.75M
4.43M
Sum Pv Ufcf
23.46M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
12.48
Free Cash Flow T1
8.14M
Terminal Value
77.64M
Present Terminal Value
43.11M
Intrinsic Value
Enterprise Value
66.58M
Net Debt
1.32M
Equity Value
65.26M
Diluted Shares Outstanding
47.27M
Equity Value Per Share
1.38
Projected DCF
1.38 -1.42%
